A Study to Investigate the Tolerability and Effect of Three Single-dose Regimens of BIA 9-1067
Phase 2
Completed
- Conditions
- Parkinson's Disease
- Interventions
- Registration Number
- NCT01568034
- Lead Sponsor
- Bial - Portela C S.A.
- Brief Summary
The purpose of this study is to investigate the effect of BIA 9-1067 on the levodopa pharmacokinetics when administered in combination with immediate release levodopa/carbidopa or levodopa/benserazide in Parkinson's Disease (PD) patients.
- Detailed Description
This was a three-centre, double-blind, randomised, placebo-controlled, crossover study with four consecutive single-dose treatment periods in PD patients treated with immediate release 100 mg/25 mg levodopa/carbidopa or 100 mg/25 mg levodopa/benserazide
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
- Male or female of non-childbearing potential (by reason of surgery or postmenopausal);
- Aged between 30 and 75 years, inclusive;
- A diagnosis of PD according to the UK PDS Brain Bank diagnostic criteria (bradykinesia and at least one of the following: muscular rigidity, rest tremor and postural instability);
- Predictable signs of end-of-dose deterioration despite "optimal" levodopa/carbidopa or levodopa/benserazide therapy;
- Been treated with a stable regimen of 3 to 8 doses of standard release 100 mg/25 mg levodopa/carbidopa or 100 mg/25 mg levodopa/benserazide per day within at least 1 week prior to randomisation;
- Modified Hoehn and Yahr stage of less than 5 in the off-state;
- Mean duration of OFF stage ≥ 1.5 h during waking hours (based on historical information);
- Concomitant anti-Parkinsonian medication (other than apomorphine, entacapone or tolcapone) in stable doses for at least 4 weeks prior to randomisation;
- Results of clinical laboratory tests acceptable by the investigator (not clinically significant for the well-being of the subject or for the purpose of the study);
- Able and willing to give written informed consent.
Exclusion Criteria
- Non-idiopathic parkinsonism (atypical parkinsonism, symptomatic parkinsonism, Parkinson-plus syndrome);
- Treated with levodopa/carbidopa or levodopa/benserazide in a 10:1 ratio, or with levodopa/carbidopa in a controlled-release formulation;
- Treated with entacapone, tolcapone, neuroleptics, antidepressants (except serotonin-specific reuptake inhibitors or imipramines [desipramine, imipramine, clomipramine and amitriptyline]), monoamine oxidase inhibitors (except selegiline up to 10 mg/day in oral formulation or 1.25 mg/day in buccal absorption formulation or rasagiline up to 1 mg/day) or antiemetics (except domperidone) within 4 weeks prior to randomisation;
- Treated with apomorphine within 7 days prior to randomisation;
- Treated with any investigational product within 2 months prior to randomisation (or within 5 half-lives, whichever is longer);
- A psychiatric or any medical condition that might place him/her at increased risk or interfere with assessments;
- Known hypersensitivity to any of the ingredients of the investigational products;
- A history of abuse of alcohol, drugs or medications within the last 2 years;
- A clinically relevant ECG abnormality;
- A history or current evidence of heart disease, including but not limited to myocardial infarction, angina, congestive heart failure and cardiac arrhythmia;
- Unstable concomitant disease being treated with changing doses of medication;
- A history or current evidence of any relevant disease in the context of this study, i.e., with respect to the safety of the subject (e.g., hepatic or renal impairment) or related to the study conditions;
- A test positive for the human immunodeficiency viruses (HIV) 1 or 2 antibodies, or hepatitis B surface antigen (HBsAg), or hepatitis C antibody (HCVAb);
- Donated blood or received blood or blood products within the 6 months prior to randomisation;
- Pregnant, breast-feeding or of childbearing potential;
- Other condition or circumstance that, in the opinion of the investigator, may compromise the subject's ability to comply with the study protocol.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Treatment Sequence C BIA 9-1067 Treatment Sequence C Period 1 - 100 mg BIA 9-1067 Period 2 - Placebo Period 3 - 25 mg BIA 9-1067 Period 4 - 50 mg BIA 9-1067 Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half Treatment Sequence A Levodopa/Carbidopa Treatment Sequence A Period 1 - 25 mg BIA 9-1067 Period 2 - 50 mg BIA 9-1067 Period 3 - 100 mg BIA 9-1067 Period 4 - Placebo Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half Treatment Sequence A Placebo Treatment Sequence A Period 1 - 25 mg BIA 9-1067 Period 2 - 50 mg BIA 9-1067 Period 3 - 100 mg BIA 9-1067 Period 4 - Placebo Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half Treatment Sequence B Levodopa/Carbidopa Treatment Sequence B Period 1 - Placebo Period 2 - 25 mg BIA 9-1067 Period 3 - 50 mg BIA 9-1067 Period 4 - 100 mg BIA 9-1067 Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half Treatment Sequence B Levodopa/Benzerazide Treatment Sequence B Period 1 - Placebo Period 2 - 25 mg BIA 9-1067 Period 3 - 50 mg BIA 9-1067 Period 4 - 100 mg BIA 9-1067 Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half Treatment Sequence A BIA 9-1067 Treatment Sequence A Period 1 - 25 mg BIA 9-1067 Period 2 - 50 mg BIA 9-1067 Period 3 - 100 mg BIA 9-1067 Period 4 - Placebo Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half Treatment Sequence C Placebo Treatment Sequence C Period 1 - 100 mg BIA 9-1067 Period 2 - Placebo Period 3 - 25 mg BIA 9-1067 Period 4 - 50 mg BIA 9-1067 Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half Treatment Sequence D Placebo Treatment Sequence D Period 1 - 50 mg BIA 9-1067 Period 2 - 100 mg BIA 9-1067 Period 3 - Placebo Period 4 - 25 mg BIA 9-1067 Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half Treatment Sequence A Levodopa/Benzerazide Treatment Sequence A Period 1 - 25 mg BIA 9-1067 Period 2 - 50 mg BIA 9-1067 Period 3 - 100 mg BIA 9-1067 Period 4 - Placebo Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half Treatment Sequence B BIA 9-1067 Treatment Sequence B Period 1 - Placebo Period 2 - 25 mg BIA 9-1067 Period 3 - 50 mg BIA 9-1067 Period 4 - 100 mg BIA 9-1067 Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half Treatment Sequence B Placebo Treatment Sequence B Period 1 - Placebo Period 2 - 25 mg BIA 9-1067 Period 3 - 50 mg BIA 9-1067 Period 4 - 100 mg BIA 9-1067 Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half Treatment Sequence C Levodopa/Benzerazide Treatment Sequence C Period 1 - 100 mg BIA 9-1067 Period 2 - Placebo Period 3 - 25 mg BIA 9-1067 Period 4 - 50 mg BIA 9-1067 Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half Treatment Sequence D Levodopa/Carbidopa Treatment Sequence D Period 1 - 50 mg BIA 9-1067 Period 2 - 100 mg BIA 9-1067 Period 3 - Placebo Period 4 - 25 mg BIA 9-1067 Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half Treatment Sequence D Levodopa/Benzerazide Treatment Sequence D Period 1 - 50 mg BIA 9-1067 Period 2 - 100 mg BIA 9-1067 Period 3 - Placebo Period 4 - 25 mg BIA 9-1067 Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half Treatment Sequence D BIA 9-1067 Treatment Sequence D Period 1 - 50 mg BIA 9-1067 Period 2 - 100 mg BIA 9-1067 Period 3 - Placebo Period 4 - 25 mg BIA 9-1067 Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half Treatment Sequence C Levodopa/Carbidopa Treatment Sequence C Period 1 - 100 mg BIA 9-1067 Period 2 - Placebo Period 3 - 25 mg BIA 9-1067 Period 4 - 50 mg BIA 9-1067 Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half
- Primary Outcome Measures
Name Time Method Tmax = Time to Cmax Day 3 Day 3 tmax = time to Cmax (values are median)
Cmax - Maximum Plasma Concentration Day 3 Day 3 Cmax - Maximum plasma concentration (ng/mL)
- Secondary Outcome Measures
Name Time Method AUC0-6 - Area Under the Plasma Concentration-time Curve From Time 0 to 6 Hours Post-dose (Day 3) Day 3 AUC0-6 - area under the plasma concentration-time curve from time 0 to 6 hours post-dose (ng.h/mL)
Trial Locations
- Locations (3)
Department of Neurology- Hospital of the department of medical care of Ministry Internal Affairs of Ukraine
🇺🇦Kyiv, Ukraine
Department of Neurology-Hospital de Santa Maria-Faculty of Medicine, University of Lisbon
🇵🇹Lisbon, Portugal
Spitalul Clinic Colentina - Clinica de Neurologie
🇷🇴Bucharest, Romania